• $6.3M
    Market Cap
  • -67.61%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
-100.00%
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-44.9M
+8.28%
-41.5M
-13.44%
-47.9M
-11.56%
-54.2M
+7.98%
Depreciation and Amortization Expense
2.2M
-24.14%
2.9M
-21.62%
3.7M
-9.76%
4.1M
-4.65%
Total Operating Expenses
57.6M
-3.57%
59.7M
-11.66%
67.6M
-10.90%
75.9M
+7.27%
Operating Profit
-57.6M
-3.57%
-59.7M
-11.66%
-67.6M
-10.90%
-75.9M
+7.27%
Interest Income
100,000
-66.67%
300,000
-62.50%
800,000
+14.29%
700,000
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
100,000
-66.67%
300,000
-62.50%
800,000
+14.29%
700,000
N/A
Total Nonoperating Income and Expense
1.8M
-56.72%
4.1M
-16.69%
4.9M
+317.86%
1.2M
-14.53%
Income before Taxes
-57.6M
-3.57%
-59.7M
-11.66%
-67.6M
-10.90%
-75.9M
+7.27%
Income Taxes
0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-55.8M
+0.34%
-55.7M
-11.27%
-62.7M
-16.07%
-74.7M
+7.70%
Net Income from Continuing Operations Applicable to Common
-55.8M
+0.34%
-55.7M
-11.27%
-62.7M
-16.07%
-74.7M
+7.70%
Basic EPS and Net Income
-19.65
+887.44%
-1.99
-11.56%
-2.25
-16.36%
-2.69
+7.17%
Diluted EPS and Net Income
-19.65
+887.44%
-1.99
-11.56%
-2.25
-16.36%
-2.69
+7.17%
Basic Weighted Average Shares
2.8M
-89.84%
28.0M
+0.46%
27.8M
+0.33%
27.7M
+0.46%
Diluted Weighted Average Shares
2.8M
-89.84%
28.0M
+0.46%
27.8M
+0.33%
27.7M
+0.46%
Balance Sheet
Cash and Cash Equivalents
26.0M
-6.29%
27.7M
+111.95%
13.1M
-50.87%
26.6M
+115.85%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
26.0M
-6.29%
27.7M
+111.95%
13.1M
-50.87%
26.6M
+115.85%
Total Current Assets
43.7M
-39.08%
71.8M
-36.30%
112.7M
-31.26%
164.0M
-28.02%
Accumulated Depreciation
25.3M
+9.46%
23.1M
+14.17%
20.2M
+21.64%
16.6M
+30.56%
Property and Plant and Equipment and Net
3.3M
-40.03%
5.5M
-39.58%
9.0M
-24.07%
11.9M
-14.97%
Total Long-Term Assets
546,000
+64.46%
332,000
-82.36%
1.9M
-42.36%
3.3M
+465.86%
Total Assets
50.2M
-37.94%
80.9M
-36.85%
128.0M
-30.47%
184.2M
-24.02%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
10.6M
+10.36%
9.6M
+39.10%
6.9M
-24.59%
9.1M
+38.12%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
0
-100.00%
Total Long-Term Liabilities
526,000
-20.42%
661,000
-15.80%
785,000
-12.68%
899,000
-78.59%
Total Liabilities
15.2M
-0.96%
15.4M
+13.01%
13.6M
-18.12%
16.6M
+84.79%
Retained Earnings
-436.0M
+14.69%
-380.1M
+17.15%
-324.5M
+23.96%
-261.8M
+39.96%
Total Stockholders Equity
34.9M
-46.63%
65.5M
-42.78%
114.4M
-31.70%
167.5M
-28.22%
Total Shares Outstanding
3.5M
-87.48%
28.0M
+0.37%
27.9M
+0.46%
27.8M
+0.34%
Cash Flow
Cash from Operating Activities
-49.6M
+21.59%
-40.8M
-22.97%
-53.0M
-1.69%
-53.9M
-5.87%
Capital Expenditures
474,000
0.00%
474,000
-42.20%
820,000
-61.25%
2.1M
-10.34%
Cash from Investing Activities
25.6M
-53.79%
55.3M
+40.83%
39.3M
-42.23%
68.0M
+85.73%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
22.3M
+15,394.44%
144,000
-6.49%
154,000
-23.00%
200,000
+106.13%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-85.23%
+59.96%
-53.28%
+32.61%
-40.18%
+14.67%
-35.04%
+38.63%
Return on Equity
-111.23%
+79.76%
-61.87%
+39.07%
-44.49%
+19.34%
-37.28%
+41.60%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
4.14
-44.80%
7.50
-54.20%
16.38
-8.85%
17.97
-47.89%
Cash Ratio
2.46
-15.09%
2.90
+52.38%
1.90
-34.86%
2.92
+56.28%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow